Health Condition 1: I10- Essential (primary) hypertension
Conditions
Interventions
Intervention1: Nil: Nil
Control Intervention1: Nil: Nil
Sponsors
Sun Pharma Laboratories Limited (SPLL)
Eligibility
Inclusion criteria
Inclusion criteria: Adult patients aged =18 years of either gender Patients with essential hypertension (SBP =140 mmHg and/or DBP =90 mmHg) and stable coronary artery disease (CAD), as diagnosed by their treating physician Patients prescribed with Metosartan CH by their treating physicians Patients with available data on blood pressure (systolic and diastolic) assessment conducted as a part of routine clinical practice at least at baseline, post-baseline follow-up visits, and up to 24±2 weeks of treatment with Metosartan CH Patients with availability of essential data such as age, gender, BMI/weight, comorbidities if any, prior history of hypertension, duration of hypertension, history of smoking/alcohol consumption (if available), concomitant medication, and laboratory data (if any relevant tests are done and report is available)
Exclusion criteria
Exclusion criteria: Patients with incomplete records with respect to the required study parameters Patients with a history of allergy or contraindications to study medication
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean change in systolic BP (SBP) and diastolic BP (DBP) from baseline to post-index (composite of Metosartan CH discontinuation, addition of new therapy, or completion of 24±2 weeks of treatment with Metosartan CH)Timepoint: Baseline to 24+/-2 Weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Mean change in systolic BP (SBP) and diastolic BP (DBP) from baseline to 24±2 Weeks of treatment with Metosartan CH Proportion of patients achieving target BP (SBP Proportion of patients achieving target SBP of Proportion of patients achieving target DBP of Mean change in systolic BP (SBP) and diastolic BP (DBP) from baseline to 24±2 weeks of treatment with Metosartan CH, upon stratification of patients by age, gender, weight/BMI, and comorbidities Proportion of patients with adverse eventsTimepoint: Baseline to 24±2 Weeks;Mean change in systolic BP (SBP) and diastolic BP (DBP) from baseline to next available follow-up visits before 24 weeks Proportion of patients achieving BP goals (SBP Proportion of patients achieving target SBP of Proportion of patients achieving target DBP of Mean change in systolic BP (SBP) and diastolic BP (DBP) from baseline to next available follow-up visits before 24 weeks, upon stratification of patients by age, gender, weight/BMI, and comorbiditiesTimepoint: Before 24 weeks | — |
Countries
India
Contacts
Public ContactMs Colette Pinto
Sun Pharma Laboratories Limited
Outcome results
None listed